Systematic (IUPAC) name
Clinical data
Pregnancy cat.  ?
Legal status Investigational
Routes Oral
CAS number 120685-11-2
ATC code None
PubChem CID 9829523
Synonyms 4'-N-benzoylstaurosporine
Chemical data
Formula C35H30N4O4 
Mol. mass 570.637 g/mol
SMILES eMolecules & PubChem

Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor).[1]

After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine.[2] In another trial, the substance has proven ineffective in metastatic melanoma.[3]


  1. ^ Fischer, T.; Stone, R. M.; Deangelo, D. J.; Galinsky, I.; Estey, E.; Lanza, C.; Fox, E.; Ehninger, G. et al. (2010). "Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome with Either Wild-Type or Mutated FLT3". Journal of Clinical Oncology 28 (28): 4339. doi:10.1200/JCO.2010.28.9678. PMID 20733134.  edit
  2. ^ ClinicalTrials.gov NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
  3. ^ Millward, M. J.; House, C.; Bowtell, D.; Webster, L.; Olver, I. N.; Gore, M.; Copeman, M.; Lynch, K. et al. (2006). "The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study". British Journal of Cancer 95 (7): 829. doi:10.1038/sj.bjc.6603331. PMC 2360547. PMID 16969355. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2360547.  edit